Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking

J. Hoggatt, Louis Pelus

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Hematopoietic stem cell (HSC) transplantation is a potentially curative treatment for numerous hematological malignancies. The transplant procedure as performed today takes advantage of HSC trafficking; either egress of HSC from the bone marrow to the peripheral blood, that is, mobilization, for acquisition of the hematopoietic graft, and/or trafficking of HSC from the peripheral blood to bone marrow niches in the recipient patient, that is HSC homing. Numerous studies, many of which are reviewed herein, have defined hematopoietic regulatory mechanisms mediated by the 20-carbon lipid family of eicosanoids, and recent evidence strongly supports a role for eicosanoids in regulation of hematopoietic trafficking, adding a new role whereby eicosanoids regulate hematopoiesis. Short-term exposure of HSC to the eicosanoid prostaglandin E 2 increases CXCR4 receptor expression, migration and in vivo homing of HSC. In contrast, cannabinoids reduce hematopoietic progenitor cell (HPC) CXCR4 expression and induce HPC mobilization when administered in vivo. Leukotrienes have been shown to alter CD34 cell adhesion, migration and regulate HSC proliferation, suggesting that eicosanoids have both opposing and complimentary roles in the regulation of hematopoiesis. As numerous FDA approved compounds regulate eicosanoid signaling or biosynthesis, the utility of eicosanoid-based therapeutic strategies to improve hematopoietic transplantation can be rapidly evaluated.

Original languageEnglish
Pages (from-to)1993-2002
Number of pages10
JournalLeukemia
Volume24
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Eicosanoids
Hematopoiesis
Hematopoietic Stem Cells
Bone Marrow
CXCR4 Receptors
Transplants
Cannabinoids
Leukotrienes
Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
Prostaglandins E
Cell Adhesion
Cell Movement
Carbon
Transplantation
Cell Proliferation
Lipids
Therapeutics

Keywords

  • eicosanoids
  • homing
  • mobilization
  • prostaglandin
  • stem cell
  • trafficking

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. / Hoggatt, J.; Pelus, Louis.

In: Leukemia, Vol. 24, No. 12, 12.2010, p. 1993-2002.

Research output: Contribution to journalArticle

Hoggatt, J. ; Pelus, Louis. / Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. In: Leukemia. 2010 ; Vol. 24, No. 12. pp. 1993-2002.
@article{a2106391366c48fa9e41761f565361fb,
title = "Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking",
abstract = "Hematopoietic stem cell (HSC) transplantation is a potentially curative treatment for numerous hematological malignancies. The transplant procedure as performed today takes advantage of HSC trafficking; either egress of HSC from the bone marrow to the peripheral blood, that is, mobilization, for acquisition of the hematopoietic graft, and/or trafficking of HSC from the peripheral blood to bone marrow niches in the recipient patient, that is HSC homing. Numerous studies, many of which are reviewed herein, have defined hematopoietic regulatory mechanisms mediated by the 20-carbon lipid family of eicosanoids, and recent evidence strongly supports a role for eicosanoids in regulation of hematopoietic trafficking, adding a new role whereby eicosanoids regulate hematopoiesis. Short-term exposure of HSC to the eicosanoid prostaglandin E 2 increases CXCR4 receptor expression, migration and in vivo homing of HSC. In contrast, cannabinoids reduce hematopoietic progenitor cell (HPC) CXCR4 expression and induce HPC mobilization when administered in vivo. Leukotrienes have been shown to alter CD34 cell adhesion, migration and regulate HSC proliferation, suggesting that eicosanoids have both opposing and complimentary roles in the regulation of hematopoiesis. As numerous FDA approved compounds regulate eicosanoid signaling or biosynthesis, the utility of eicosanoid-based therapeutic strategies to improve hematopoietic transplantation can be rapidly evaluated.",
keywords = "eicosanoids, homing, mobilization, prostaglandin, stem cell, trafficking",
author = "J. Hoggatt and Louis Pelus",
year = "2010",
month = "12",
doi = "10.1038/leu.2010.216",
language = "English",
volume = "24",
pages = "1993--2002",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking

AU - Hoggatt, J.

AU - Pelus, Louis

PY - 2010/12

Y1 - 2010/12

N2 - Hematopoietic stem cell (HSC) transplantation is a potentially curative treatment for numerous hematological malignancies. The transplant procedure as performed today takes advantage of HSC trafficking; either egress of HSC from the bone marrow to the peripheral blood, that is, mobilization, for acquisition of the hematopoietic graft, and/or trafficking of HSC from the peripheral blood to bone marrow niches in the recipient patient, that is HSC homing. Numerous studies, many of which are reviewed herein, have defined hematopoietic regulatory mechanisms mediated by the 20-carbon lipid family of eicosanoids, and recent evidence strongly supports a role for eicosanoids in regulation of hematopoietic trafficking, adding a new role whereby eicosanoids regulate hematopoiesis. Short-term exposure of HSC to the eicosanoid prostaglandin E 2 increases CXCR4 receptor expression, migration and in vivo homing of HSC. In contrast, cannabinoids reduce hematopoietic progenitor cell (HPC) CXCR4 expression and induce HPC mobilization when administered in vivo. Leukotrienes have been shown to alter CD34 cell adhesion, migration and regulate HSC proliferation, suggesting that eicosanoids have both opposing and complimentary roles in the regulation of hematopoiesis. As numerous FDA approved compounds regulate eicosanoid signaling or biosynthesis, the utility of eicosanoid-based therapeutic strategies to improve hematopoietic transplantation can be rapidly evaluated.

AB - Hematopoietic stem cell (HSC) transplantation is a potentially curative treatment for numerous hematological malignancies. The transplant procedure as performed today takes advantage of HSC trafficking; either egress of HSC from the bone marrow to the peripheral blood, that is, mobilization, for acquisition of the hematopoietic graft, and/or trafficking of HSC from the peripheral blood to bone marrow niches in the recipient patient, that is HSC homing. Numerous studies, many of which are reviewed herein, have defined hematopoietic regulatory mechanisms mediated by the 20-carbon lipid family of eicosanoids, and recent evidence strongly supports a role for eicosanoids in regulation of hematopoietic trafficking, adding a new role whereby eicosanoids regulate hematopoiesis. Short-term exposure of HSC to the eicosanoid prostaglandin E 2 increases CXCR4 receptor expression, migration and in vivo homing of HSC. In contrast, cannabinoids reduce hematopoietic progenitor cell (HPC) CXCR4 expression and induce HPC mobilization when administered in vivo. Leukotrienes have been shown to alter CD34 cell adhesion, migration and regulate HSC proliferation, suggesting that eicosanoids have both opposing and complimentary roles in the regulation of hematopoiesis. As numerous FDA approved compounds regulate eicosanoid signaling or biosynthesis, the utility of eicosanoid-based therapeutic strategies to improve hematopoietic transplantation can be rapidly evaluated.

KW - eicosanoids

KW - homing

KW - mobilization

KW - prostaglandin

KW - stem cell

KW - trafficking

UR - http://www.scopus.com/inward/record.url?scp=78650309579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650309579&partnerID=8YFLogxK

U2 - 10.1038/leu.2010.216

DO - 10.1038/leu.2010.216

M3 - Article

C2 - 20882043

AN - SCOPUS:78650309579

VL - 24

SP - 1993

EP - 2002

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -